QOL Medical, LLC Withdrawal from CMS National Rebate Agreement

Effective October 1, 2011, QOL Medical has opted out of the CMS (Centers for Medicare & Medicaid Services) National Rebate Agreement.

As new information regarding this decision becomes available, it will be posted on this page. Additionally, healthcare professionals may register to receive updates via email below.

Please read the FAQ Sheet provided below as it may assist you with any questions you may have related to this decision and what options are available in regards to support services.

Letter to Physicians
FAQ’s

Register to Receive Updates

Healthcare professionals wishing to stay current on the latest information related to Sucraid^® (sacrosidase) Oral Solution and this decision may register below to receive periodic updates via email.

Name:*

Address:*

Address (cont'd):

City:*

State:*

Zip Code:*

Primary Telephone:*

Email:*

Qualification & License #:*

	Yes, I am a licensed healthcare professional
	Yes, please send me updates regarding the QOL Medical withdrawal from the CMS National Rebate Agreement.

*Denotes required field

Important Safety Information

For a complete discussion of indications, usage, contraindications, warnings, precautions, adverse reactions, and overdosage, please see full prescribing information attached. Do not use Sucraid^{^®} with patients known to be hypersensitive to yeast, yeast products, or glycerin (glycerol). Sucraid may contain papain which can cause allergic reactions in some patients. Adverse experiences with Sucraid in clinical trials were generally minor and were frequently associated with underlying disease. In clinical studies of up to 54 months duration, physicians treated a total of 52 patients with Sucraid. The adverse experiences and respective number of patients reporting each event were as follows: abdominal pain(4), vomiting(3), nausea(2), diarrhea(2), constipation(2), insomnia(1), headache(1), nervousness(1), and dehydration(1). Note: diarrhea and abdominal pain can be a part of the clinical presentation of the genetically determined sucrase deficiency, which is part of congenital sucrase-isomaltase deficiency. The effects of Sucraid have not been evaluated in patients with secondary (acquired) disaccharidase deficiency. In one clinical trial, one patient, a four year old boy who was being treated for asthma, experienced severe wheezing necessitating admission into the ICU. While reported reactions are extremely rare, care should be taken when administering initial doses of Sucraid to observe any signs of acute hypersensitivity reaction. Care should be taken to administer initial doses of Sucraid near a facility where acute hypersensitivity reactions can be adequately treated.¹